LISATA THERAPEUTICS, INC. — Director's Dealing 2015

Dec 23, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2015-12-22

Reporting Person: MYERS STEVEN S (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-12-22	Common stock, par value $0.001 per share	A	150000	—	Acquired	302931	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock, par value $0.001 per share	84331	Indirect
Common stock, par value $0.001 per share	8012	Indirect
Common stock, par value $0.001 per share	19531	Indirect

Footnotes

F1: On December 22, 2015 (the "Grant Date"), the Reporting Person was granted an award of 150,000 shares of the Company's common stock (the "Shares"), subject to all of the terms and conditions of the Company's 2015 Equity Compensation Plan (the "Plan"). The Shares vest as to 50,000 shares upon the Grant Date and 25,000 shares per quarter on the last day of each quarter, commencing March 31, 2016, so long as he remains Chairman, until fully vested.